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Abstract Type 2 diabetes mellitus (T2DM) is a major risk
factor for cardiovascular disease (CVD) morbidity and
mortality worldwide. Renin-angiotensin system (RAS)
blockers have been indispensable in diminishing the
macrovascular and microvascular complications of diabe-
tes. In addition, cumulative evidence from retrospective
studies pointed toward a beneficial effect of RAS agents in
preventing the development and progression of T2DM.
This disease-modifying potential of RAS blockers has been
substantiated by recent prospective trials. Contemporary
concepts regarding the natural history of T2DM and the
pathophysiologic processes involved have increased our
understanding of the mechanisms underlying the therapeu-
tic potential of these agents in diabetes management. In
addition to their established roles in the primary prevention
of CVD in patients with diabetes, RAS blockers might be
considered a suitable therapeutic choice for preventing the
development of frank diabetes in high-risk patients.
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Clinical Trial Acronyms
ALLHAT Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial
CHARM Candesartan in Heart Failure-Assessment
of Reduction in Mortality and Morbidity
DREAM Diabetes Reduction Assessment with
Ramipril and Rosiglitazone Medication
HOPE Heart Outcomes Prevention Evaluation
INVEST International Verapamil SR-Trandolapril
Study
LIFE Losartan Intervention for Endpoint
Reduction in Hypertension
NAVIGATOR Nateglinide and Valsartan in Impaired
Glucose Tolerance Outcomes Research
ONTARGET Ongoing Telmisartan Alone and in
Combination with Ramipril Global
Endpoint Trial
SCOPE Study on Cognition and Prognosis in the
Elderly
Introduction
Diabetes mellitus afflicts an estimated 6.6% of the global
adult population, or approximately 285 million individuals.
This is projected to increase by more than 50% to a 7.8%
worldwide prevalence in 20 years. Unless this trend is
curbed, the diabetes pandemic will remain an enormous
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DOI 10.1007/s11886-010-0138-1public health and economic burden. As a major risk factor
for cardiovascular disease (CVD) and as a coronary artery
disease (CAD)–equivalent, diabetes is associated with a
multitude of macrovascular and microvascular complica-
tions. It is a leading cause of premature death, and
approximately 6.8% of adult deaths worldwide are
attributed to diabetes [1].
Renin-angiotensin system (RAS) agents, which in-
clude angiotensin-converting enzyme inhibitors (ACEIs)
and angiotensin receptor blockers (ARBs), are mainstay
therapies for hypertension. They are also known to
prevent the macrovascular and microvascular complica-
tions in both hypertensive and normotensive individuals
with diabetes. Recently, a growing body of evidence has
emerged that suggests that RAS agents may have a direct
role in preventing the development of abnormal glucose
homeostasis and in directly altering the natural history of
type 2 diabetes mellitus (T2DM). The promise of this
therapeutic approach merits a closer scrutiny, considering
the potential implications on the primary and secondary
prevention strategies for CVD.
Pathogenesis of Type 2 Diabetes
T2DM, previously referred to as adult-onset or non–
insulin-dependent diabetes, is characterized by a triad of
metabolic derangements: 1) insulin resistance, 2) relative
impairment in insulin secretion that is not autoimmune-
mediated, and 3) hyperglycemia from increased hepatic
gluconeogenesis. The etiogenesis of these metabolic abnor-
malities is poorly understood, but both genetic and
environmental factors play important roles [2]. A family
history of diabetes is a strong risk factor for the subsequent
development of the disease, exerting a profound genetic
influence on the phenotype of patients with T2DM [3].
Ethnicity-related differences in susceptibility exist, with
minority ethnic groups such as the American Indians,
Pacific Islanders, Asians, Hispanics, and blacks at a
particularly higher risk for developing the disease compared
with the Caucasian population [4]. Several acquired factors
also play a role in the pathogenesis of the disease, including
unhealthy dietary patterns, hypertension, obesity [5],
smoking [6], and a sedentary lifestyle [7].
Of the three underlying metabolic defects involved in
diabetes pathogenesis, insulin resistance is the generally
accepted primary mechanism responsible for T2DM and is
perhaps the best predictor for it [8]. It is characterized by a
subnormal response to a given concentration of insulin,
blunting the normal glucose uptake by skeletal muscles and
fat cells. A higher fasting plasma insulin level usually
indicates a higher degree of insulin resistance. Insulin
resistance is thought to be principally genetically linked,
although other factors such as obesity, hypertension, or
advancing age may play a role [9].
Impaired insulin secretion, the other crucial metabolic
event in T2DM, determines the progression and ultimately
directs the course of the disease. It is caused by pancreatic
β-cell dysfunction, the exact mechanisms for which remain
not entirely clear. Derangement in insulin secretion has
been demonstrated with abnormalities of the GLUT protein
(which partly mediates glucose transport into the pancreatic
β cell to stimulate insulin production) [10], as well as
deficiency of the ABCA1 protein (an adenosine triphos-
phate–binding cholesterol transporter in the β cell) [11].
More recently, experimental evidence has highlighted the
possible role of oxidative stress in causing β-cell damage
and reduced insulin secretory function [12].
The impairment in insulin secretion results in hypergly-
cemia that, in chronic states, can be toxic to the β cell,
leading to further reduction of insulin secretion. Also,
hyperglycemia in itself exacerbates insulin resistance [13],
perpetuating the vicious metabolic cycle. Diabetic patients
present with a combination of varying degrees of insulin
resistance and eventually relative insulin deficiency, and
whatever the underlying mechanisms, the full phenotypic
expression of T2DM requires both insulin resistance and
β-cell dysfunction.
The Natural History of Type 2 Diabetes
Insulin resistance is the initial metabolic event that
eventually leads to T2DM (Fig. 1), and it precedes the
development of hyperglycemia by several years [14]. The
pancreatic β cell, for a period of time, compensates by
increasing insulin levels (hyperinsulinemia), which keeps
the individual normoglycemic during the initial phase of the
disease. These initial metabolic events manifest clinically as
mild postprandial hyperglycemia (impaired glucose toler-
ance [IGT]) and/or mild elevation of fasting plasma glucose
levels (impaired fasting glucose [IFG]) [15].
Both IGT and IFG serve as markers for individuals at
greatest risk for developing T2DM. It was previously
thought that they represented the asymptomatic stages
along the continuum between normal glucose tolerance
and frank diabetes. Recent data, however, suggest that IGT
and IFG are distinct phenotypic pathways that separately
lead to the development of diabetes [16, 17]. Although
these prediabetes conditions feature dysfunctions in both
insulin sensitivity and secretion, they differ in the degree,
sites, and patterns by which these metabolic defects
manifest. Patients with isolated IGT have severe skeletal
muscle insulin resistance with normal (or only mildly
impaired) hepatic sensitivity, whereas those with isolated
IFG predominantly have hepatic insulin resistance with
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early and late phases of insulin secretory responses are
abnormal, leading to prolonged hyperglycemia after a
glucose load. In those with isolated IFG, there is reduction
in the early phase of insulin secretory response, which
causes fasting hyperglycemia; however, the late phase
response is preserved, which allows the normalization of
blood sugar levels after a glucose load.
Combined IGT-IFG states are common. Roughly 25%
of patients with prediabetes develop frank T2DM, about
25% revert to normoglycemia, and the remaining half
remain in this impaired glycemic state [18]. Although
asymptomatic, these “prediabetes” conditions are poten-
tially pathologic, and in themselves could induce vascular
damage and CVD. Nevertheless, both disorders, when
diagnosed early, can be reversible and provide an
important window in which appropriate intervention may
halt the progression to full-blown diabetes [19].
During the transition from prediabetes to T2DM,
insulin resistance becomes more severe, a progression that
may be due not only to full expression of genetic defects,
but also to acquired factors such as obesity, decreased
physical activity, and aging. This is accompanied by an
increase in basal hepatic glucose production. β-Cell
exhaustion eventually occurs, resulting in inadequate
insulin secretion, and ultimately hyperglycemia. This
failure of the β cell over time to compensate for insulin
resistance with hyperinsulinemia marks the beginning of
T2DM. As β-cell function progressively declines an
absolute insulin deficiency de v e l o p s ,w h i c hc o u l dl e a dt o
a stage in which exogenous insulin is required to maintain
adequate glycemic control [2].
Microvascular and Microvascular Complications
of Diabetes
Morbidity from T2DM is generally grouped into the
microvascular and macrovascular complications. The mi-
crovascular disorders include diabetic retinopathy, neurop-
athy, and nephropathy. The macrovascular complications
include CAD, stroke, and peripheral vascular disease.
Retinopathy is generally considered the most common
microvascular complication of diabetes, accounting for an
estimated 10,000 new cases of blindness annually in the
United States [20]. Diabetic nephropathy is the leading cause
of renal failure, and afflicts roughly 40% of patients with
diabetes [21]. Approximately 30% of patients with diabetes
also suffer from some form of neuropathy [22], which is
responsible for a large proportion of limb amputations.
The risk for developing microvascular complications of
diabetes is thought to be related more directly to glucose,
and depends on both the duration and the severity of
hyperglycemia. The exact pathologic mechanisms are
unclear, but one of those postulated includes osmotic stress
from sorbitol accumulation. High glucose levels increase
the flux of sugar molecules through the polyol pathway,
which converts glucose into glucose alcohol (sorbitol)
inside the cell. This pathway, mediated by the aldose
reductase enzyme, causes intracellular sorbitol accumula-
tion and subsequent cell damage. Furthermore, hypergly-
cemia is thought to promote the nonenzymatic formation of
advanced glycosylated end products, substances that have
been demonstrated to cause cellular injury. High glucose
levels can also stimulate free radical production and induce
oxidative stress, as well as incite the pathologic release of
different growth factors [23].
DiabetesisastrongindependentriskfactorforCVD,andis
in fact considered a CAD-equivalent. At least 65% of patients
with diabetes die from heart disease or stroke. Mortality rates
from CVD in diabetic patients are two to four times higher
compared with nondiabetic patients [24]. The risk of CVD
events is disproportionately higher in women with T2DM,
with increases in rates of myocardial infarction (MI) up to
4.5-fold and stroke up to sixfold, compared with twofold and
1.5-fold increases in MI and stroke risks, respectively, in
diabetic men [25]. The Framingham study showed that
diabetes takes away the entire gender protection for macro-
vascular disease afforded to women [26].
Fig. 1 The postulated natural progression from normoglycemic state
to frank type 2 diabetes is shown. The numbered items indicate the
hypothetical sequence of adverse metabolic events that are associated
with the development of the disease
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unquestioned, the underlying mechanisms for the macro-
vascular complications are not as well defined. Atheroscle-
rosis is the central pathophysiologic process involved, and
is thought to result from chronic inflammation and injury to
the coronary, cerebral, and peripheral arterial walls,
stimulating atheromatous plaque formation. Progressive
plaque deposition leads to chronic vessel stenosis, whereas
rupture of this atherosclerotic lesion results in acute
vascular syndromes. T2DM is associated with atherogenic
dyslipidemia, which consists of high triglyceride, low high-
density lipoprotein, and preponderance of small dense low-
density lipoprotein particles, all of which can contribute to
the development of atherosclerosis. Additionally, diabetes
is associated with increased platelet adhesion (from free
radical formation, impaired nitric oxide (NO) generation,
and calcium dysregulation) as well as hypercoagulability
(from elevated levels of plasminogen activator inhibitor).
This combination of increased coagulability and impaired
fibrinolysis further predisposes to CVD events [27].
RAS Agents and Prevention of Diabetic Complications
The beneficial effects of RAS agents in the prevention of
microvascular and macrovascular complications ofT2DM are
well established, making them mainstay therapies in the
management of diabetic patients, as recommended by current
primary and secondary prevention guidelines [28]. In a
substudy of patients with T2DM in the HOPE trial, ACEI
therapy using ramipril resulted in reductions in MI by 22%,
stroke by 33%, cardiovascular mortality by 37%, and
nephropathy by 24% compared with placebo [29]. Treatment
with ARB has also been shown to have vasculoprotective
effects, as shown in the LIFE study in which losartan was
associated with reductions in MI by 19%, stroke by 22%,
cardiovascular mortality by 38%, and albuminuria by 46%
compared with atenolol in diabetic patients [30].
RAS Agents in the Prevention of Diabetes Development
and Progression
In addition to the mitigation of diabetic complications, there
is also mounting evidence, mostly from post hoc analyses
of early large randomized trials, on the role of RAS agents
in modifying the natural course of diabetes itself. The
HOPE study, for example, showed that compared with
placebo, the ACEI ramipril was associated with a 34%
reduction in self-reported incident diabetes in patients at
high risk for CVD events [31]. In the ALLHAT trial,
nondiabetic patients who were treated with the ACEI
lisinopril had a significantly lower rate of development of
new diabetes after 2 years compared with those given
amlodipine and chlorthalidone [32]. Similarly, the ACEI
trandolapril, when added to other antihypertensive agents,
was found to significantly reduce the risk of incident
diabetes, and appeared to neutralize the dysglycemic effects
associated with thiazides in the INVEST study involving
patients without diabetes at baseline [33].
Treatment with ARBs appeared to have the same effect
as ACEIs in preventing the development of diabetes. In
hypertensive nondiabetic patients, the risk of new-onset
diabetes was reduced by 25% with losartan therapy in the
LIFE study [34], and by 20% with candesartan in the
SCOPE [35]. In patients with heart failure, analysis of data
from the CHARM program showed that ARB therapy was
associated with a 29% reduction in incident diabetes [36].
A systematic review of 22 trials of antihypertensive drugs
involvingover143,000nondiabeticpatientsfoundthatamong
the different classes of antihypertensive agents, the RAS
blockers were associated with the highest reduction in the risk
ofdevelopmentofdiabetes(reductionsof33%withACEIand
43% with ARB) [37]. Data from the ONTARGET trial [38],
which studied over 25,000 patients with CVD, demonstrated
similar rates of incident diabetes with ACEI or ARB
treatment, and that combination therapy with ACEI and
ARB did not lead to further reduction in the incidence of
new-onset diabetes or CVD events compared to treatment
with either agent alone. It was estimated that an average of
45 patients would need to be treated with RAS agents over 4
to 5 years to avoid one new case of T2DM [39].
Mechanisms for Diabetes-Modifying Properties of RAS
Agents
The glycometabolic effects of ACEIs are purported to be
modulated by their actions on bradykinin, NO, and
angiotensin II (AT II). Bradykinin has been shown to
increase insulin sensitivity and enhance skeletal muscle
glucose uptake by activating B2 kinin receptors in the
muscle cells [40] and by upregulating the GLUT glucose
transport system [41]. Bradykinin-potentiated glucose up-
take has been demonstrated in cardiac tissue as well [42].
NO is purported to mediate insulin-related glucose uptake
through the same mechanisms as bradykinin (Fig. 2). In
addition, NO also appears to be the primary mediator for
the non–insulin-dependent transport and utilization of
glucose in the skeletal muscle [43]. AT II, a powerful
vasoconstrictor and growth factor, can interfere with the
normal insulin signaling pathway through serine phosphor-
ylation of specific insulin receptors in the muscle cell
(Fig. 3), contributing to the insulin resistance observed in
essential hypertension [44]. AT II is also a strong mediator
of oxidative stress via the NADPH pathway [45].
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increasing the levels of circulating AT II. Being biochem-
ically identical to the kininase II enzyme, ACE also
promotes the degradation of bradykinin [46], leading to
reductions in both bradykinin and NO levels. Treatment
with ACEI agents, by blocking the actions of ACE, causes
reduction in the levels of AT II, as well as increase in the
levels of bradykinin and NO, which results not only in
vasodilatation but also enhanced insulin insensitivity and
improved cellular glucose uptake.
ARBs, conversely, are able to attenuate the negative
effects of AT II on cellular insulin signaling by specifically
inhibiting the AT II type 1 receptors. The ARB-related
improvement in insulin-stimulated glucose uptake has been
documented not only in muscle and hepatic cells, but in
adipose tissue as well [47]. ARBs have also been shown to
have beneficial outcomes on glucose metabolism, which are
independent of their effects on AT II receptors, and are
thought to be related to their partial agonism of peroxisome
proliferator-activated receptors [48]. Thus, the protection
against type 2 diabetes afforded by some ARBs may be
partially linked to a thiazolidinedione-like effect.
ItisspeculatedthatthehemodynamicactionofRASagents
on the microcirculation leads to increased blood flows to the
skeletal muscle (resulting in increased insulin sensitivity) and
to the pancreatic islet cells (resulting in increased insulin
secretion). RAS agents have also been shown to reduce
sympathetic activity, modulate changes in muscle fiber
composition, and improve the ionic homeostasis of potassium
and magnesium, all of which may contribute to favorable
changes in insulin release and sensitivity [49].
Recently, attention has focused on the role of ARBs in the
preservation of pancreatic β-cell function. Experimental
modelshaveshownthatARB treatmentresultedinsignificant
reductions in reactive oxygen species, protein kinase C, and
NADPH oxidase activities in pancreatic islet cells, leading to
enhancedβ-cell survival[50, 51]. The protection afforded by
ARBs against the deleterious effects of inflammatory and
oxidative stress was associated with increased β-cell mass,
augmented insulin secretion, and improved glucose toler-
ance. Furthermore, ARB therapy was also shown to prevent
the loss of endothelial cells and reduce fibrosis in and around
the islets [52]. Despite these multiple postulated mecha-
nisms, however, the precise processes by which the RAS
blockers exert their favorable effects on glucose metabolism
in humans are still not established.
Recent Clinical Evidence on the Role of RAS Blockers
in Diabetes Prevention
Although retrospective studies pointed to a consistent bene-
ficial effect of RAS agents on the development and
progression of diabetes, recent randomized trials that pro-
spectively evaluated this effect showed somewhat less
convincingresults.IntheDREAM[53] study, which enrolled
nearly 5300 patients with prediabetes, treatment with the
ACEI ramipril was associated with a 16% higher likelihood
of regression of IGT and/or IFG to normoglycemia. There
was a trend toward a reduced incidence of new-onset
Fig. 3 Shows the cross-talk between the insulin signaling pathway and
the angiotensin II type 1 receptor, in which the metabolic effects of
insulin are antagonized, but the proliferative effects are not. CoA—
coenzyme A; MAPK—mitogen-activated protein kinase; PI3—
phosphatidylinositol-3
 
Fig. 2 Shows the sites of action of the renin-angiotensin system
blockers in relation to the different mediators that are thought to have
favorable (bradykinin, nitric oxide) or deleterious (angiotensin II)
effects on insulin sensitivity and/or secretion. ACE—angiotensin-
converting enzyme
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however, this did not reach statistical significance.
The recently published results of the NAVIGATOR [54￿]
trial showed more positive findings in favor of the ARB
valsartan. This international, multicenter, double-blind, ran-
domized study enrolled over 9300 subjects with IGT and/or
IFG having or known CVD who were treated with valsartan
or nateglinide for an average of 5 years. Although there was
no beneficial effect of the antidiabetic medication nategli-
nide, treatment with valsartan was associated with a 14%
reduction in the incidence of new-onset diabetes. However,
there was no significant difference in the rates of CVD
events compared with placebo after 5 years of follow-up.
One possible reason that could explain the observed
differences in results between the ACEI and ARB trials was
the shorter follow-up period in DREAM (3 years) com-
pared with NAVIGATOR (5 years). Also, although both
studies enrolled patients with prediabetes, the subjects of
the DREAM trial appeared to have lesser risk profiles.
Hypertension, a major risk factor for diabetes development,
was present in only 43% of DREAM patients, as opposed
to 77% in NAVIGATOR. All subjects of the NAVIGATOR
trial had pre-existing CVD (if 50 years of age or older), or
one or more CVD risk factors (if 55 years of age or older).
Younger patients (30 years minimum age) were recruited in
the DREAM study, and those with pre-existing CVD were
excluded. Because of the disparity in subject selection, it is
thought that NAVIGATOR likely enrolled significantly
more patients with overactive RAS compared with
DREAM, which could partially account for the dispropor-
tionate results seen with RAS blockade.
Although the prospective studies showed that both ACEI
and ARB do have favorable glycometabolic effects, similar
to those suggested by the earlier retrospective analyses,
they failed to demonstrate the beneficial effects of RAS
agents on “harder” end points in patients with prediabetes
and/or the presence of CVD risk factors. The lack of
favorable effect on harder end points could potentially be
related to the relatively short follow-up periods. These
results do corroborate the assertion that RAS blockers have
the potential to prevent the progression of prediabetes
conditions to frank T2DM.
Implications to Clinical Practice
The value of RAS agents in preventing CVD events and other
complications related to diabetes is established. That they
provide additional, albeit modest, benefit in terms of
modifying the natural history of T2DM only strengthens their
position as a viable first-line therapeutic option in diabetes as
well as prediabetes conditions. For the primary prevention of
CVD inT2DM, current standards ofmedical carerecommend
thatACEIorARBbeadministeredtoalldiabeticpatientswith
hypertension [28]. Furthermore, the guidelines also advocate
the use of RAS blockers for the prevention of diabetic
nephropathy, especially in those with microalbuminuria [55].
For the prevention of T2DM in high-risk individuals, the
American Diabetes Association has approved only one drug
(metformin) so far for this purpose, citing cost, safety, and
efficacyissuesrelatedtotheotherpotentialagents[18]. Given
the preponderance of evidence pointing to the potential
beneficial effects of ACEIs and ARBs on glycometabolic
parameters, it is reasonable to consider these agents to
prevent progression to diabetes in high-risk individuals with
IGT or IFG. It is conceivable that future updates to the
management guidelines might include the use of RAS agents
in patients with prediabetes or metabolic syndrome.
Conclusions
As a major risk factor for CVD morbidity and mortality
worldwide, the T2DM pandemic is a major global public
health concern. RAS blockers have been indispensable in
diminishing the macrovascular and microvascular complica-
tions of diabetes. Cumulative evidence from retrospective
studies pointed toward a beneficial effect of RAS agents in
preventing the development and progression of the disease,
and this has been substantiated by recent prospective trials.
ContemporaryconceptsregardingthenaturalhistoryofT2DM
and the pathophysiologic processes involved have increased
our understanding of the mechanisms underlying the thera-
peutic potential of these agents in diabetes management. In
addition to their established roles in the primary prevention of
CVD in patients with diabetes, RAS blockers might be
considered a suitable therapeutic choice for the prevention of
diabetes development in high-risk patients with IGTor IFG.
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